202 related articles for article (PubMed ID: 37165926)
21. A case of primary malignant melanoma of the esophagogastric junction with abscopal effect after nivolumab administration.
Yamaguchi T; Fushida S; Kinoshita J; Saito H; Shimada M; Terai S; Moriyama H; Okamoto K; Nakamura K; Ninomiya I; Inaki N
Surg Case Rep; 2021 Dec; 7(1):253. PubMed ID: 34882298
[TBL] [Abstract][Full Text] [Related]
22. Differential abscopal effect in extracranial and intracranial lesions after radiotherapy alone for vertebral bone metastasis of unknown primary: a case report.
Ishikawa Y; Umezawa R; Yamamoto T; Takahashi N; Takeda K; Suzuki Y; Jingu K
J Med Case Rep; 2022 Mar; 16(1):94. PubMed ID: 35248152
[TBL] [Abstract][Full Text] [Related]
23. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion: dose distribution and clinical outcome.
Ishida Y; Sakanaka K; Fujii K; Itasaka S; Mizowaki T
J Radiat Res; 2019 Jul; 60(4):517-526. PubMed ID: 31083715
[TBL] [Abstract][Full Text] [Related]
24. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Zhu H; Rivin Del Campo E; Ye J; Simone CB; Zhu Z; Zhao W; Amini A; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Mo M; Jia H; Lu S; Wang J; Nie Y; Chen J; Wu S; Hamaji M; Haque W; Jeong BK; Shridhar R; Zhang Z; Chen Y; Zhao K
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1396-1406. PubMed ID: 33677048
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
Sun D; Liu D; Liu Q; Hou H
Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
[TBL] [Abstract][Full Text] [Related]
26. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
27. Radiotherapy-induced abscopal effect on the metastatic carcinoma of unknown primary origin: a case report and literature review.
Guo Z; Zhou J; Guo H; Liu LK
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4634-4637. PubMed ID: 35856353
[TBL] [Abstract][Full Text] [Related]
28. Effect of bilateral supraclavicular postoperative radiotherapy in middle and lower thoracic esophageal carcinoma.
Ren Y; Su C; Zhou Y; Zhao X; Yang CL; Liu YY
World J Gastroenterol; 2014 Dec; 20(47):17970-5. PubMed ID: 25548496
[TBL] [Abstract][Full Text] [Related]
29. Successful Treatment of Advanced Gastric Cancer with Brain Metastases through an Abscopal Effect by Radiation and Immune Checkpoint Inhibitor Therapy.
Muto M; Nakata H; Ishigaki K; Tachibana S; Yoshida M; Muto M; Yanagawa N; Okumura T
J Gastric Cancer; 2021 Sep; 21(3):319-324. PubMed ID: 34691815
[TBL] [Abstract][Full Text] [Related]
30. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
[TBL] [Abstract][Full Text] [Related]
31. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
[TBL] [Abstract][Full Text] [Related]
32. Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report.
Fiorica F; Belluomini L; Giuliani J; Urbini B; Milella M; Frassoldati A; Pilotto S; Giorgi C
Immunotherapy; 2021 Aug; 13(12):971-976. PubMed ID: 34180714
[TBL] [Abstract][Full Text] [Related]
33. A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.
Wu X; Hu X; Chen J; He L
Radiat Oncol; 2021 Jun; 16(1):100. PubMed ID: 34103059
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
35. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
[TBL] [Abstract][Full Text] [Related]
36. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy.
Xu X; Wang Z; Jiang S; Shang Y; Wu Y
Radiat Oncol; 2019 Nov; 14(1):191. PubMed ID: 31684983
[TBL] [Abstract][Full Text] [Related]
37. Mapping patterns of metastatic lymph nodes for postoperative radiotherapy in thoracic esophageal squamous cell carcinoma: a recommendation for clinical target volume definition.
Yu J; Ouyang W; Li C; Shen J; Xu Y; Zhang J; Xie C
BMC Cancer; 2019 Sep; 19(1):927. PubMed ID: 31533656
[TBL] [Abstract][Full Text] [Related]
38. Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.
McBride S; Sherman E; Tsai CJ; Baxi S; Aghalar J; Eng J; Zhi WI; McFarland D; Michel LS; Young R; Lefkowitz R; Spielsinger D; Zhang Z; Flynn J; Dunn L; Ho A; Riaz N; Pfister D; Lee N
J Clin Oncol; 2021 Jan; 39(1):30-37. PubMed ID: 32822275
[TBL] [Abstract][Full Text] [Related]
39. Pattern of relapse following three-field lymphadenectomy of esophageal carcinoma and related factors predictive of recurrence.
Xu ZC; Su BA; Li JC; Cheng WF; Chen J
Cancer Radiother; 2023 May; 27(3):189-195. PubMed ID: 36754752
[TBL] [Abstract][Full Text] [Related]
40. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
